Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: European Medicines Agency (EMA) | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals | Rituxan | Treanda